How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07]

[Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 528. 2017 Final publication URL Indexing Status Subject indexing assigned

2017 Health Technology Assessment (HTA) Database.

102. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites (...) therapy for psoriasis 2017. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-36. [17 references] This is the current release of the guideline. This guideline updates

2017 National Guideline Clearinghouse (partial archive)

103. Biologic therapy for psoriasis

Biologic therapy for psoriasis British Association of Dermatologists FULL VERSION Guidelines for biologic therapy for psoriasis Methods, evidence and recommendations April 2017 NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the processes described in Updated guidance for writing a British Association of Dermatologists (...) : Evidence tables clinical studies 227 Appendix F: Forest plots 296 Appendix G: Stakeholders 342 Appendix H: Study selection flow charts 343 Appendix I: GRADE tables 349 Appendix J: Choice of biologic treatment for psoriasis (decision aid) 385 Appendix K: Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV 389 British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 1 Guideline Development Group members Name Role CLINICAL Ms Tracy Bale British

2017 British Association of Dermatologists

104. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2016 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Final Evidence Report December 2, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 Page ii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table (...) Institute for Clinical and Economic Review, 2016 Page iii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents Disclosure Statement: Dr. Linder owns stock in Amgen, Biogen, and Eli Lily, has contingent value rights in Sanofi Genzyme (related to alemtuzumab for multiple sclerosis); in the past 3 years, Dr. Linder has received grant support from Astellas Pharma on an unrelated topic (overactive bladder) and Clintrex, which

2017 California Technology Assessment Forum

105. Topical steroids better than vitamin D for treating scalp psoriasis

Topical steroids better than vitamin D for treating scalp psoriasis Topical steroids better than vitamin D for treating scalp psoriasis Discover Portal Discover Portal Topical steroids better than vitamin D for treating scalp psoriasis Published on 14 June 2016 doi: Topical steroids applied to the scalp were more effective and safer for treating psoriasis than topical vitamin D alone. Using steroids in combination with vitamin D was statistically better than using a steroid alone (...) , but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59

2019 NIHR Dissemination Centre

106. Biological therapies for psoriasis do not increase serious infection risk

Biological therapies for psoriasis do not increase serious infection risk Biological therapies for psoriasis do not increase serious infection risk Discover Portal Discover Portal Biological therapies for psoriasis do not increase serious infection risk Published on 23 January 2018 doi: People with psoriasis who take an immune-modulating treatment are no more likely to get serious infections than people taking standard therapies. There are fears that these biological therapies raise the risk (...) of serious infections and this has discouraged their use. They are recommended by NICE for moderate to severe psoriasis. Previous studies have reached conflicting conclusions, making it hard to advise on the true risk. This study used a large database of people with psoriasis from the UK and Ireland. It compared serious infection risk of the biological therapies (etanercept, adalimumab or ustekinumab) with non-biological therapies, after accounting for factors such as other illnesses. It found none

2019 NIHR Dissemination Centre

107. Apremilast for treating moderate to severe plaque psoriasis

Apremilast for treating moderate to severe plaque psoriasis Apremilast for treating moder Apremilast for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta419 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Apremilast for treating moderate to severe plaque psoriasis (TA419) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 32Contents Contents 1 Recommendations 4 2 The technology 5 3

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

108. Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis

Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis '); } else { document.write(' '); } ACE | Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis Search > > Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis - Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis Published on 3 May 2017 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has not recommended (...) ustekinumab to be listed on the Medication Assistance Fund (MAF) for the treatment of chronic plaque psoriasis and psoriatic arthritis. Factors considered to inform the recommendation for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis. The Agency for Care Effectiveness conducted the evaluation in consultation

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

109. Psoriasis

Psoriasis EDF Guidelines Secretariat to Professor Dr. Nast: Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charite.de European S3-Guideline on the Systemic Treatment of Psoriasis vulgaris Update Apremilast and Secukinumab EDF in cooperation with EADV and IPC Subcommittee Members: Prof. Dr (...) ) Prof. Dr. Annegret Kuhn, Muenster (Germany) Prof. Dr. Andreas Wollenberg, Munich (Germany) Prof. Dr. Marcus Maurer, Berlin (Germany) Prof. Dr. Christos Zouboulis, Dessau (Germany) Prof. Dr. Dieter Metze, Muenster (Germany) Prof. Dr. Dr. Torsten Zuberbier, Berlin (Germany) Prof. Dr. Kai Munte, Rotterdam (Netherlands) Chairman of EDF Guideline Committee: PD Dr. Alexander Nast, Berlin (Germany) Expiry date: 08/2020 European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update

2017 European Dermatology Forum

110. To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical

2018 Clinical Trials

111. Prevalence of genital psoriasis in patients with psoriasis. Full Text available with Trip Pro

Prevalence of genital psoriasis in patients with psoriasis. Psoriatic lesions in the genital area (GenPs) can cause considerable physical and emotional distress. To increase physician awareness, we estimated the GenPs prevalence among patients with psoriasis.An English language literature search was performed. Articles reporting GenPs prevalence met the search criteria and were included. Because GenPs is rarely reported in demographics of prospective clinical trials, GenPs prevalence (...) and baseline demographics of patients with and without GenPs in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801) involving patients with moderate-to-severe psoriasis are reported.Overall, 600 references were screened. Eighteen articles met the search criteria. Patient populations were highly heterogeneous across articles. Broadly, the presence of GenPs was either physician-reported (physical examinations) or patient-reported (questionnaires). In the literature, GenPs prevalence

2018 Journal of Dermatological Treatment

112. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. (Abstract)

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. Psoriasis is a chronic, inflammatory skin disease and has significant associated morbidity and effect on quality of life. It is important to determine whether dietary interventions help reduce disease severity in patients with psoriatic diseases.To make evidence-based dietary recommendations for adults with psoriasis and/or psoriatic (...) arthritis from the Medical Board of the National Psoriasis Foundation.We used literature from prior systematic reviews as well as additional primary literature from the MEDLINE database from January 1, 2014, to August 31, 2017, that evaluated the impact of diet on psoriasis. We included observational and interventional studies of patients with psoriasis or psoriatic arthritis. The quality of included studies was assessed using the Newcastle-Ottawa scale for observational studies and the Cochrane Risk

2018 JAMA dermatology (Chicago, Ill.)

113. Association of Psoriasis With Comorbidity Development in Children With Psoriasis. Full Text available with Trip Pro

Association of Psoriasis With Comorbidity Development in Children With Psoriasis. Children with psoriasis are at increased risk for comorbidities. Many children with psoriasis are also overweight or obese; it is unknown whether the increased risk of comorbidities in these children is independent of obesity.To determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease (...) , and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity.This was a retrospective cohort study of claims data from Optum Laboratories Data Warehouse (includes 150 million privately insured and Medicare enrollees). A cohort of 29 957 children with psoriasis (affected children) and an age-, sex-, and race-matched comparator cohort of 29 957 children without psoriasis were identified and divided into 4 groups: (1) nonobese, without psoriasis (reference cohort); (2

2018 JAMA dermatology (Chicago, Ill.)

114. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. (Abstract)

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD.To assess therapeutic options for patients with psoriasis and concurrent IBD.A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis (...) , psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected.Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic

2018 Journal of American Academy of Dermatology

115. CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents. (Abstract)

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents. Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led (...) to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education

2018 Journal of American Academy of Dermatology

116. The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study). (Abstract)

The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study). Psychological aspect and quality of life should be considered in treating patients with psoriasis.We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality (...) of life (HRQoL) in patients with psoriasis.The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1260 adult patients with psoriasis. In addition to clinical characteristics including presence of exposed lesions, data were collected using the Psoriatic Arthritis (PsA) Screening and Evaluation (PASE), Dermatology Life Quality Index (DLQI), MOS 36-Item Short-Form Health Survey (SF-36), Work Productivity and Activity Impairment Questionnaire Psoriasis

2018 Journal of the European Academy of Dermatology and Venereology

117. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Our objective was to compare therapeutic response among patients with early-onset psoriasis (EOP) and late-onset psoriasis (LOP) receiving adalimumab, etanercept, infliximab, ustekinumab, or methotrexate in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Patients were grouped by age of onset: EOP (age ≤ 40 years) or LOP (age > 40 years (...) ). Repeated-measures analysis with logistic regression was used to calculate the adjusted odds ratio (AOR; adjusted for baseline characteristics) for achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) or a percentage of body surface area involved with psoriasis < 3% (%BSA < 3) or %BSA < 1 for all patients; similar sensitivity analyses were performed for each treatment group.Of 7511 patients, 5479 (72.9%) had EOP. The LOP group had a higher likelihood of achieving PGA 0/1 after

2018 American journal of clinical dermatology

118. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin. Full Text available with Trip Pro

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin. Resident T cells are implicated in the maintenance and recurrence of psoriatic lesions. Whether skin that has not yet experienced psoriasis in patients with established disease harbors pathogenic T cells is less investigated.We sought to analyze the composition of resident T cells and T cell-driven tissue responses in skin never affected by psoriasis from patients with mild (...) disease.Never-lesional skin from patients with psoriasis (NLP) was collected from those with mild disease. T-cell profiles were assessed by using confocal imaging and flow cytometry. Tissue responses to T-cell stimulation were measured by using multiplex and NanoString technology.T-cell activation ex vivo triggered psoriasiform and type I interferon tissue responses in NLP psoriasis. Accordingly, keratinocytes from NLP responded to IFN-γ stimulation with myxovirus 1 (MX1) expression and IFN-α release

2018 Journal of Allergy and Clinical Immunology

119. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Full Text available with Trip Pro

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.To describe patients' experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication (...) with physicians, satisfaction with treatment and concerns regarding treatment options.The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively.Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only

2018 Journal of the European Academy of Dermatology and Venereology

120. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA Full Text available with Trip Pro

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis (...) assessments.The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87

2018 Psoriasis: Targets and Therapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>